| Send an email AGAIN with questions to IR and our MR. L Tanguy (who never answered!!!)
They must have known that it would be a disaster, yet they keep on claiming the great???? future of the product!!! They definetely lied about what was going on!
And now suddenly Bloomberg is totally off ???? In the past, their numbers were consistently too low, and now they are way off and too high????
I don't take those false assesments no more !!
SPCEO1 - (10/8/2019 11:41:18 AM)
Trogarzo sales situation The explanation for the actual sales versus expectations we had of better numbers based on the Bloomberg new patient numbers is that the bloomberg new patient numbers are incorrect. Apparently, if you have a Trogarzo prescription already and you need to renew it every three months, bloomberg captures that renewal as a "new prescription" thereby giving us false hope.
So, they have added new patients but nowhere near as many as bloomberg has suggested.
They did have a great June and June Trogarzo sales did exceed Egrifta's, but obviously that was an anomaly (likely both on the low side for Egrifta and the high side for Trogarzo).
The fall-off from June to July and August is still hard to comprehend and inventory adjustments seem to be the only explanation.
The expectations for Trogarzo sales have fallen a long way since the drug was launched. I have to believe we have finally seen the bottom in those falling expectations. While the company is still holding onto their forecast for long term Trogarzo sales being 5 times those of Egrifta currently (or roughly greater thean $190 million) there really does not seem to be a good reason to believe that will happen, especially now that we know the bloomberg new patient numbers are not legit.
Meanwhile, my best guess would be that the much higher profit margin Egrifta sales expectations will prove to be too low once the new version is launched and the Grinspoonarticle is published. |